First-generation, E1-deleted adenovirus subtype 5 (Ad5)-based vectors, although promising
platforms for use as cancer vaccines, are impeded in activity by naturally occurring or …

We have investigated if immunotherapy against human papilloma virus (HPV) using a viral
gene delivery platform to immunize against HPV 16 genes E6 and E7 (Ad5 [E1-, E2b-]-E6/E7) …

Extracorporeal immunoadsorption of plasma to remove IgG and circulating immune
complexes (CIC) was evaluated as a therapy for adults with treatment-resistant immune …

We have developed a COVID-19 vaccine, hAd5 S-Fusion + N-ETSD, that expresses SARS-CoV-2
spike (S) and nucleocapsid (N) proteins with modifications to increase immune …

Background. Chemotherapy‐associated thrombotic thrombocytopenic purpura/hemolytic
uremic syndrome (C‐TTP/HUS) is a condition involving thrombocytopenia, microangiopathic …

In response to the health crisis presented by the COVID-19 pandemic, rapid development of
safe and effective vaccines that elicit durable immune responses is imperative. Recent …

… Joseph P. Balint is a shareholder and employee of Etubics and has stock options in the
Company. Elizabeth S. Gabitzsch is a shareholder and employee of Etubics and has stock …

Adenovirus serotype 5 (Ad5) has been widely used in clinical trials because it expresses
inserted transgenes robustly and augments the innate immune response. Strategies to improve …

We have developed a dual-antigen COVID-19 vaccine incorporating genes for a modified
SARS-CoV-2 spike protein (S-Fusion) and the viral nucleocapsid (N) protein with an …

Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms in
numerous animal and human clinical studies. The immune response induced by Ad5 …